Petersen B M, Bass B L, Bates H R, Chandeysson P L, Harmon J W
Surgical Service, Department of Veterans Affairs Medical Center, Washington, DC 20422.
Am J Surg. 1993 Jan;165(1):137-42; discussion 142-3. doi: 10.1016/s0002-9610(05)80417-9.
Monoclonal antibodies directed at tumor-associated antigens may be useful adjuncts for the management of patients with colorectal cancer. The murine monoclonal antibody, B72.3, binds Tag-72, a cell-surface antigen, which is expressed by colorectal carcinoma cells. We investigated the benefit of indium-111-labeled B72.3, 111In-CYT-103, in localizing the presence and extent of disease in patients with suspected or biopsy-proven primary colorectal cancer and in patients with apparently localized recurrent colorectal adenocarcinoma. Twenty patients were enrolled in this study. Each patient received 1 mg of B72.3 labeled with 4 to 5 mCi of 111In. Patients then underwent planar and single-photon emission computed tomographic imaging 2 to 5 days after infusion. Fifteen patients underwent surgery 1 to 14 days after scanning. There were 11 true positives, 1 false positive, 2 true negatives, and 1 false negative. The 111In-CYT-103 scan correctly identified the presence or absence of tumor in the 15 patients in whom biopsies were obtained, for an accuracy rate of 87%. Overall, 111In-CYT-103 supplied clinically useful information regarding the extent of disease that was not previously reported by standard techniques in 33% (5 of 15) of patients who underwent surgical exploration. We conclude that 111In-CYT-103 is a promising imaging agent for patients with potentially resectable recurrences and for those patients with a presumed isolated primary tumor requiring preoperative staging.
针对肿瘤相关抗原的单克隆抗体可能是结直肠癌患者管理的有用辅助手段。鼠单克隆抗体B72.3可结合Tag-72，一种由结肠癌细胞表达的细胞表面抗原。我们研究了铟-111标记的B72.3（111In-CYT-103）在疑似或经活检证实的原发性结直肠癌患者以及明显局限性复发性结肠直肠腺癌患者中定位疾病存在和范围的益处。本研究纳入了20名患者。每位患者接受1毫克用4至5毫居里的111In标记的B72.3。患者在输注后2至5天接受平面和单光子发射计算机断层扫描成像。15名患者在扫描后1至14天接受手术。有11例假阳性、1例假阴性、2例真阴性和1例真阳性。111In-CYT-103扫描在15名获得活检的患者中正确识别了肿瘤的存在与否，准确率为87%。总体而言，在接受手术探查的患者中，33%（15名中的5名）的患者中，111In-CYT-103提供了有关疾病范围的临床有用信息，而这些信息以前标准技术未报告过。我们得出结论，111In-CYT-103对于有潜在可切除复发的患者以及那些假定为孤立原发性肿瘤需要术前分期评估的患者是一种有前景的成像剂。
